Unique Track Record

Our Company, Our Experience

value_chain_sym

Symbiotics' mission is to contribute to job creation and the economic development of micro, small and medium-sized enterprises, particularly those active in areas related to food, homes, jobs and energy working in a sustainable manner. We achieve this goal by offering investments in partner microfinance and SME impact institutions to our clients. We provide three complementary and independent business proposals: research and advisory services, asset management services and brokerage and structuring services. Each activity is managed by a separate legal entity and staff. In addition, there is a corporate unit providing support to all three businesses.

structure

Since its launch in Geneva, Switzerland in December 2004, Symbiotics has:

  • positioned itself as a leader in microfinance investment and SME impact investment services
  • offered financial intermediation services to over 27 investment funds specialized in microfinance, in addition to institutional investors and development banks
  • invested over 1 billion dollars in microfinance and the development of small and medium enterprises since 2005
  • visited and analyzed over 668 financial institutions, investing in over 127, in over 40 emerging countries
  • funded over 531,495 micro-, small and medium-sized enterprises, thereby indirectly supporting the access to capital and financial services to over 2 million people from low-income households
  • created Symbiotics Asset Management, an asset management company that has outpeformed industry benchmarks since its launch in 2008
  • designed and developed Syminvest.com, the largest online research and brokerage platform in the microfinance and SME impact investing industry
  • hired more than 95 experts in 4 continents , working in our offices in Cape Town, Geneva, Mexico City and Singapore
In this section


Our business units
In this section
 

Legal Disclaimer: The collective investment schemes (the “Investment Products”) referred to on the following pages have not been approved for public distribution in or from Switzerland by the Swiss Financial Market Supervisory Authority (FINMA) pursuant to the Swiss Collective Investment Schemes Act of 23 June 2006 (the "CISA") and its implementing regulations. Accordingly, units of such Investment Products and information, documents or material pertaining to these Investment Products on the following pages may only be distributed in or from Switzerland to qualified investors (as such term is defined in the CISA and its implementing regulations). The information, documents and material pertaining to these Investment Products on the following pages are strictly confidential and do not constitute an offer to any other person or entity than Swiss qualified investors and may only be used by those qualified investors who have accessed them. They may not be copied, used by, distributed or made available to any other person.

Similarly the information on the following pages is only intended to be viewed by persons who fall outside the scope of any law that seeks to regulate financial promotions in the country of your residence or in the country in which the content of this website is being viewed.

If you are uncertain about your position under the laws of the country in which the content of this website is being viewed then you should seek clarification by obtaining legal advice from a lawyer practicing in the country of your residence or in the country in which the content of this website is being viewed before accessing this website.

The information, documents and material contained in the following pages are not warranted to be accurate, complete, or timely. More specifically, Symbiotics SA may not be held responsible for and does not take any position with respect to the accuracy and completeness of information in the following pages.

Agree    Disagree